The spinal antinociceptive effects of endomorphins in rats: Behavioral and G protein functional studies

Anesthesia and Analgesia

Volumn 106, Issue 6, 2008, Pages 1873-1881

  Xie, Hong ^a,b   Woods, James H ^a   Traynor, John R ^a   Ko, Mei Chuan ^a,c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c NATIONAL CHENGCHI UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BINALTORPHIMINE; DELTA OPIATE RECEPTOR; ENDOMORPHIN 1; ENDOMORPHIN 2; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); KAPPA OPIATE RECEPTOR; MU OPIATE RECEPTOR; NALTREXONE; NALTRINDOLE; RECEPTOR PROTEIN; ANALGESIC AGENT; DRUG DERIVATIVE; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST; NORBINALTORPHIMINE; OLIGOPEPTIDE; SULFUR;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; BRAIN MEMBRANE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; INFLAMMATION; MALE; NOCICEPTION; NONHUMAN; PAIN; PARTIAL AGONISM; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; RAT; SPINAL CORD; TAIL FLICK TEST; THALAMUS; ANIMAL; COMPARATIVE STUDY; DISEASE MODEL; DRUG POTENTIATION; INTRASPINAL DRUG ADMINISTRATION; METABOLISM; PAIN ASSESSMENT; SPRAGUE DAWLEY RAT; TIME;

ANALGESICS; ANALGESICS, OPIOID; ANIMALS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG PARTIAL AGONISM; ENKEPHALIN, ALA(2)-MEPHE(4)-GLY(5)-; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); INJECTIONS, SPINAL; MALE; NALTREXONE; NARCOTIC ANTAGONISTS; OLIGOPEPTIDES; PAIN; PAIN MEASUREMENT; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID, MU; SPINAL CORD; SULFUR RADIOISOTOPES; THALAMUS; TIME FACTORS;

EID: 44649139859     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/ane.0b013e31817300be     Document Type: Article

References (46)

1. Inturrisi CE. Clinical pharmacology of opioids for pain. Clin J Pain 2002;18:S3-13
2. Zollner C, Stein C. Opioids. Handb Exp Pharmacol 2007;177:31-63
3. Bennett G, Serafini M, Burchiel K, Buchser E, Classen A, Deer T, Du Pen S, Ferrante FM, Hassenbusch SJ, Lou L, Maeyaert J, Penn R, Portenoy RK, Rauck R, Willis KD, Yaksh T. Evidencebased review of the literature on intrathecal delivery of pain medication. J Pain Symptom Manage 2000;20:S12-36
4. Dougherty PM, Staats PS. Intrathecal drug therapy for chronic pain: from basic science to clinical practice. Anesthesiology 1999;91:1891-918
5. Rathmell JP, Lair TR, Nauman B. The role of intrathecal drugs in the treatment of acute pain. Anesth Analg 2005;101:S30-43
6. Negri L, Melchiorri P, Lattanzi R. Pharmacology of amphibian opiate peptides. Peptides 2000;21:1639-47
7. Zadina JE, Hackler L, Ge LJ, Kastin AJ. A potent and selective endogenous agonist for the μ-opiate receptor. Nature 1997;386: 499-502
8. Hackler L, Zadina JE, Ge LJ, Kastin AJ. Isolation of relatively large amounts of endomorphin-1 and endomorphin-2 from human brain cortex. Peptides 1997;18:1635-39
9. Horvath G. Endomorphin-1 and endomorphin-2: pharmacology of the selective endogenous μ-opioid receptor agonists. Pharmacol Ther 2000;88:437-63
10. Fichna J, Janecka A, Costentin J, Do Rego JC. The endomorphin system and its evolving neurophysiological role. Pharmacol Rev 2007;59:88-123
11. Alt A, Mansour A, Akil H, Medzihradsky F, Traynor JR, Woods JH. Stimulation of guanosine-5′-O-(3-[35S]thio)triphosphate binding by endogenous opioids acting at a cloned mu receptor. J Pharmacol Exp Ther 1998;286:282-88
12. Narita M, Mizoguchi H, Oji GS, Tseng EL, Suganuma C, Nagase H, Tseng LF. Characterization of endomorphin-1 and -2 on [35S]GTPγS binding in the mouse spinal cord. Eur J Pharmacol 1998;351:383-387
13. Burford NT, Tolbert LM, Sadee W. Specific G protein activation and mu-opioid receptor internalization caused by morphine, DAMGO and endomorphin-1. Eur J Pharmacol 1998;342:123-26
14. Fichna J, do-Rego JC, Kosson P, Schiller PW, Costentin J, Janecka A. [35S]GTPγS binding stimulated by endomorphin-2 and morphiceptin analogs. Biochem Biophys Res Commun 2006;345:162-68
15. Stone LS, Fairbanks CA, Laughlin TM, Nguyen HO, Bushy TM, Wessendorf MW, Wilcox GL. Spinal analgesic actions of the new endogenous opioid peptides endomorphin-1 and endomorphin-2. Neuroreport 1997;8:3131-35
16. Horvath G, Szikszay M, Tomboly C, Benedek G. Antinociceptive effects of intrathecal endomorphin-1 and -2 in rats. Life Sci 1999;65:2635-41
17. Przewlocka B, Mika J, Labuz D, Toth G, Przewlocki R. Spinal analgesic action of endomorphins in acute, inflammatory and neuropathic pain in rats. Eur J Pharmacol 1999;367:189-196
18. Tseng LF, Narita M, Suganuma C, Mizoguchi H, Ohsawa M, Nagase H, Kampine JP. Differential antinociceptive effects of endomorphin-1 and endomorphin-2 in the mouse. J Pharmacol Exp Ther 2000;292:576-83
19. Emmerson PJ, Clark MJ, Mansour A, Akil H, Woods JH, Medzihradsky F. Characterization of opioid agonist efficacy in a C6 glioma cell line expressing the μ opioid receptor. J Pharmacol Exp Ther 1996;278:1121-27
20. Selley DE, Sim LJ, Xiao R, Liu Q, Childers SR. μ-opioid receptorstimulated guanosine-5′;-O-(gamma-thio)-triphosphate binding in rat thalamus and cultured cell lines: signal transduction mechanisms underlying agonist efficacy. Mol Pharmacol 1997;51:87-96
21. Sim LJ, Liu Q, Childers SR, Selley DE. Endomorphin-stimulated [35S]GTPγS binding in rat brain: Evidence for partial agonist activity at μ-opioid receptors. J Neurochem 1998;70:1567-76
22. Ko MCH, Lee H, Harrison C, Clark MJ, Song HF, Naughton NN, Woods JH, Traynor JR. Studies of μ-, κ-, and δ-opioid receptor density and G protein activation in the cortex and thalamus of monkeys. J Pharmacol Exp Ther 2003;306:179-86
23. Walker EA, Zernig G, Young EA. In vivo apparent affinity and efficacy estimates for mu opiates in a rat tail-withdrawal assay. Psychopharmacology 1998;136:15-23
24. Kovelowski CJ, Ossipov MH, Hruby VJ, Porreca F. Lesions of the dorsolateral funiculus block supraspinal opioid delta receptor mediated antinociception in the rat. Pain 1999;83:115-22
25. Zhang C, Tall JM, Meyer RA, Raja SN. Antiallodynic effects of systemic and intrathecal morphine in the spared nerve injury model of neuropathic pain in rats. Anesthesiology 2004;100:905-11
26. Miaskowski C, Sutters KA, Taiwo YO, Levine JD. Antinociceptive and motor effects of delta/mu and kappa/mu combinations of intrathecal opioid agonists. Pain 1992;49:137-44
27. Takemori AE, Ho BY, Naeseth JS, Portoghese PS. Norbinaltorphimine, a highly selective kappa-opioid antagonist in analgesic and receptor binding assays. J Pharmacol Exp Ther 1988;246:255-8
28. Chang KJ, Rigdon GC, Howard JL, McNutt RW. A novel, potent and selective nonpeptidic delta opioid receptor agonist BW373U86. J Pharmacol Exp Ther 1993;267:852-7
29. Lee H, Naughton NN, Woods JH, Ko MCH. Characterization of scratching responses in rats following centrally administered morphine or bombesin. Behav Pharamcol 2003;14:501-8
30. Zhang HN, Torregrossa MM, Jutkiewicz EM, Shi YG, Rice KC, Woods JH, Watson SJ, Ko MCH. Endogenous opioids upregulate brain-derived neurotrophic factor mRNA through δ- and μ-opioid receptors independent of antidepressant-like effect. Eur J Neurosci 2006;23:984-94
31. Parsons CG, Headley PM. Spinal antinociceptive actions of muand kappa-opioids: the importance of stimulus intensity in determining "selectivity" between reflexes to different modalities of noxious stimulus. Br J Pharmacol 1998;98:523-32
32. Morgan D, Cook CD, Picker MJ. Sensitivity to the discriminative stimulus and antinociceptive effects of mu opioids: role of strain of rat, stimulus intensity, and intrinsic efficacy at the mu opioid receptor. J Pharmacol Exp Ther 1999;289:965-75
33. Maher CE, Selley DE, Childers SR. Relationship of mu opioid receptor binding to activation of G-proteins in specific rat brain regions. Biochem Pharmacol 2000;59:1395-401
34. Saeki S, Yaksh TL. Suppression of nociceptive responses by spinal mu opioid agonists: effects of stimulus intensity and agonist efficacy. Anesth Analg 1993;77:265-74
35. Dirig DM, Yaksh TL. Differential right shifts in the doseresponse curve for intrathecal morphine and sufentanil as a function of stimulus intensity. Pain 1995;62:321-8
36. Sakurada S, Hayashi T, Yuhki M, Orito T, Zadina JE, Kastin AJ, Fujimura T, Murayama K, Sakurada C, Sakurada T, Narita M, Suzuki T, Tan-No K, Tseng LF. Differential antinociceptive effects induced by intrathecally administered endomorphin-1 and endomorphin-2 in the mouse. Eur J Pharmacol 2001;427:203-10
37. Tomboly C, Peter A, Toth G. In vitro quantitative study of the degredation of endomorphins Peptides 2002;23:1573-80
38. Sakurada C, Sakurada S, Hayashi T, Katsuyama S, Tan-No K, Sakurada T. Degradation of endomorphin-2 at the supraspinal level in mice is initiated by dipeptidyl peptidase IV: an in vitro and in vivo assay. Biochem Pharmacol 2003;66:653-61
39. Janecka A, Kruszynski R, Fichna J, Kosson P, Janecki T. Enzymatic degradation studies of endomorphin-2 and its analogs containing N-methylated amino acids. Peptides 2006;27:131-35
40. Fujita T, Kumamoto E. Inhibition by endomorphin-1 and endomorphin-2 of excitatory transmission in adult rat substantia gelatinosa neurons. Neuroscience 2006;139:1095-105
41. Soignier RD, Vaccarino AL, Brennan AM, Kastin AJ, Zadina JE. Analgesic effects of endomorphin-1 and endomorphin-2 in the formalin test in mice. Life Sci 2000;67:907-12
42. Hao JX, Yu W, Wiesenfeld-Hallin Z, Xu XJ. Treatment of chronic allodynia in spinally injured rats: effects of intrathecal selective opioid receptor agonists. Pain 1998;75:209-17
43. Ko MCH, Song MS, Edwards T, Lee H, Naughton NN. The role of central mu opioid receptors in opioid-induced itch in primates. J Pharmacol Exp Ther 2004;310:169-76
44. Yamaguchi T, Kitagawa K, Kuraishi Y. Itch-associated response and antinociception induced by intracisternal endomorphins in mice. Jpn J Pharmacol 1998;78:337-43
45. Simon EJ. Opioid receptors and endogenous opioid peptides. Med Res Rev 1991;11:357-74
46. Zhang S, Tong Y, Tian M, Dehaven RN, Cortesburgos L, Mansson E, Simonin F, Kieffer B, Yu L. Dynorphin A as a potential endogenous ligand for four members of the opioid receptor gene family. J Pharmacol Exp Ther 1998;286:136-41